Chinese Journal of Cancer(2016年12期)
癌癥(英文版)

目 錄

• About the Cover
• Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma
• Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma
• Combination therapy in cancer:effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics
• Defeating cancer:the 150 most important questions in cancer research and clinical oncology
• Development and validation of a nomogram for predicting the survival of patients with non-metastatic nasopharyngeal carcinoma after curative treatment
• MicroRNA-506 is up-regulated in the development of pancreatic ductal adenocarcinoma and is associated with attenuated disease progression
• Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy
• The clinical association of programmed cell death protein 4(PDCD4) with solid tumors and its prognostic significance:a meta-analysis
• Phase Ⅱ open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma
• ABO blood group is a predictor of survival in patients with laryngeal cancer
• New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma:a retrospective study
• Prognostic value and predictive threshold of tumor volume for patients with locally advanced nasopharyngeal carcinoma receiving intensity-modulated radiotherapy
• Study protocol of the Asian XELIRI ProjecT(AXEPT):a multinational,randomized,non-inferiority,phase Ⅲ trial of second-line chemotherapy for metastatic colorectal cancer, comparing the eicacy and safety of XELIRI with or without bevacizumab versus FOLFIRI w
• Phase Ⅰ/Ⅱ trial evaluating concurrent carbon-ion radiotherapy plus chemotherapy for salvage treatment of locally recurrent nasopharyngeal carcinoma
• Information for Authors